Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart

Basic Research in Cardiology

Volumn 98, Issue 6, 2003, Pages 401-405

  Frascarelli, Sabina ^a   Ghelardoni, Sandra ^a   Ronca Testoni, Simonetta ^a   Zucchi, Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Ghrelin; Growth hormone; Hexarelin; Ischemia; Protein kinase C

Indexed keywords

CHELERYTHRINE; DIOCTANOIN; GHRELIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; HEXARELIN; IBUTAMOREN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RECOMBINANT GROWTH HORMONE; TRIPHENYLTETRAZOLIUM;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; ENZYME ACTIVATION; GROWTH HORMONE RELEASE; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; RAT; STAINING;

ANIMALS; CARDIOTONIC AGENTS; GROWTH HORMONE; HEART; HEMODYNAMIC PHENOMENA; INDOLES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; OLIGOPEPTIDES; PEPTIDE HORMONES; RATS; RATS, WISTAR; SPIRO COMPOUNDS;

EID: 0242383502     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00395-003-0434-7     Document Type: Article

References (21)

1. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E (1999) Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 22: 266-272
2. Bodart V, Bouchard JF, McNicoll N, Escher E, Carriere P, Ghigo E, Sejlitz T, Sirois MG, Lamontagne D, Ong H (1999) Identification and characterization of a new growth-hormone releasing peptide receptor in the heart. Circ Res 85: 796-802
3. Broglio F, Benso A, Valetto MR, Gottero C, Quaranta L, Podio V, Arvat E, Bobbio M, Bisi G, Ghigo E (2001) Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrine 14: 105-108
4. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP (2002) Foods fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87: 2984
5. Houck WV, Pan LC, Kribbs SB, Clair MJ, McDaniel GM, Krombach RS, Merritt WM, Pirie C, Iannini JP, Mukherjee R, Spinale FG (1999) Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation 100: 2003-2009
6. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI et al. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273: 974-977
7. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone acylated peptide from stomach. Nature 402: 656-660
8. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Muller EE, Berti F (1999) Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 140: 4024-4031
9. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K (2001) Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 86: 5854-5859
10. Nakano A, Cohen MV, Downey JM (2000) Ischemic preconditioning: From basic mechanisms to clinical applications. Pharmacol Ther 86: 263-75
11. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-198
12. Papotti M, Ghè C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, Muccioli G (2000) Growth hormone secratagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85: 3803-3807
13. Rossoni G, De Gennaro Colonna , Bernareggi M, Polvani GL, Muller EE, Berti F (1998) Protectant effect of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol 32: 260-265
14. Smith RG, Van Der Ploeg LXT, Howard AD, Feighner SD, Cheng K, Hickey G, Wyvratt MJ, Fisher MH, Nargund RP, Patchett AA (1997) Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18: 621-645
15. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, Hjalmarson A, Bengtsson BA, Isgaard J (2000) The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 141: 60-66
16. Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodends. Nature 407: 908-913
17. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50: 707-709
18. 2+ channels. Circ Res 74: 271-280
19. 2+ release in rat heart: Implications for ischemic preconditioning. Circ Res 83: 908-915
20. Baines CP, Pass JM, Ping P (2001) Protein kinases and kinase-modulated effectors in the late phase of ischemic preconditioning. Basic Res Cardiol 96: 207-218
21. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK 1/2 and PI 3-kinase/AKT. J Cell Biol 159: 1029-1037